Terminal Phenoxy Group as a Privileged Moiety of the Drug Scaffold-A Short Review of Most Recent Studies 2013-2022.
Paweł KozyraMonika PituchaPublished in: International journal of molecular sciences (2022)
The terminal phenoxy group is a moiety of many drugs in use today. Numerous literature reports indicated its crucial importance for biological activity; thus, it is a privileged scaffold in medicinal chemistry. This review focuses on the latest achievements in the field of novel potential agents bearing a terminal phenoxy group in 2013-2022. The article provided information on neurological, anticancer, potential lymphoma agent, anti-HIV, antimicrobial, antiparasitic, analgesic, anti-diabetic as well as larvicidal, cholesterol esterase inhibitors, and antithrombotic or agonistic activities towards the adrenergic receptor. Additionally, for selected agents, the Structure-Activity-Relationship (SAR) is also discussed. Thus, this study may help the readers to better understand the nature of the phenoxy group, which will translate into rational drug design and the development of a more efficient drug. To the best of our knowledge, this is the first review devoted to an in-depth analysis of the various activities of compounds bearing terminal phenoxy moiety.
Keyphrases
- adverse drug
- structure activity relationship
- healthcare
- systematic review
- antiretroviral therapy
- human immunodeficiency virus
- hepatitis c virus
- diffuse large b cell lymphoma
- hiv positive
- hiv infected
- atrial fibrillation
- risk assessment
- optical coherence tomography
- spinal cord injury
- social media
- neuropathic pain
- spinal cord
- south africa
- brain injury
- drug discovery